Immunotherapy after second surgery shows promise for head and neck cancer
NCT ID NCT03355560
First seen May 08, 2026 · Last updated May 12, 2026 · Updated 1 time
Summary
This study tested the drug nivolumab in 39 people with head and neck cancer who had already received radiation and then had a second surgery to remove remaining cancer. The goal was to see if nivolumab is safe and helps control the disease after surgery. Participants received nivolumab for up to a year, and researchers tracked side effects and cancer outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
UC Health
Cincinnati, Ohio, 45219, United States
Conditions
Explore the condition pages connected to this study.